#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

### **SCHEDULE 14A**

### Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X] Filed by a Party other than the Registrant [ ]

Check the appropriate box:

- [ ] Preliminary Proxy Statement
- [ ] Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2))
- [ ] Definitive Proxy Statement
- [X] Definitive Additional Materials
- [ ] Soliciting Material Pursuant to 14a-12

## VistaGen Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- [X] No fee required.
- [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
- 1. Title of each class of securities to which transaction applies:
- 2. Aggregate number of securities to which transaction applies:
- 3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- 4. Proposed maximum aggregate value of transaction:
- 5. Total fee paid:
- [ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- 1. Amount Previously Paid:
- 2. Form, Schedule or Registration Statement No.:
- 3. Filing Party:
- 4. Date Filed:





Online

Go to **www.envisionreports.com/VTGN** or scan the OR code – login details are located in the shaded bar below.

Notice of	the 2020 A	nnual Meeting of Stockholders		
v	/istaGen The	Important Notice Regarding the Availability rapeutics, Inc. 2020 Annual Meeting of Stocki		iber 17, 2020
Company) 20	20 Annual Mee	nge Commission rules, you are receiving this notice that ting of Stockholders (the <i>Annual Meeting</i> ) are availat request a copy. The items to be voted on and locatio	ole on the Internet. Follow the inst	tructions below to view the
you to access and Proxy Sta	s and review al atement, Vista	is only an overview of the more complete proxy mate I of the important information contained in the proxy Gen Therapeutics Form 14A – Notice, VistaGen Therape Id March 31, 2020 are available at:	materials before voting. The 202	O Notice of Annual Meeting
		www.envisionreports.	com/VTGN	
	Easy Online Access – View your proxy materials and vote.			
1	Step 1:	Go to www.envisionreports.com/VTGN.		
$\sim$ –	Step 2:	Click on Cast Your Vote or Request Materials.		
	Step 3:	Follow the instructions on the screen to log in.		22
	Step 4: Step 5:	Make your selections as instructed on each scre Vote your shares.	en for your delivery preference	!5.
When y	you go online,	you can also help the environment by consenting	) to receive electronic delivery	of future materials.
	Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before September 7, 2020 to facilitate timely delivery.			
		2 N O T		+
	034R2C			

#### Notice of the 2020 Annual Meeting of Stockholders

VistaGen Therapeutics, Inc.'s (the *Company*) 2020 Annual Meeting of Stockholders (the *Annual Meeting*) will be held on Thursday, September 17, 2020, 10:00 A.M. PST, virtually via the internet at www.meetingcenter.io/280599481. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. The password for this meeting is – VTGN2020.

#### Proposals to be voted on at the Annual Meeting are listed below along with the Board of Directors' recommendations.

The Board of Directors recommends a vote FOR each Director nominee identified under Proposal No. 1, and FOR Proposal No. 2:

1. ELECTION OF DIRECTORS. Nominees: Jon S. Saxe, Ann M. Cunningham, Jerry B. Gin, Shawn K. Singh, H. Ralph Snodgrass, Brian J. Underdown. 2. RATIFYING THE APPOINTMENT OF OUM & CO. LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING MARCH 31, 2021.

PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card.



# Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- Internet Go to www.envisionreports.com/VTGN. Click Cast Your Vote or Request Materials.
- Phone Call us free of charge at 1-866-641-4276.
- Email Send an email to investorvote@computershare.com with "Proxy Materials VistaGen Therapeutics, Inc." in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by September 7, 2020.